Isomorphic Labs raises $5 billion to move AI-designed drugs toward human trials
Series C
A large fundraising round for a growing company.
IsoDDE
Isomorphic Labs’ AI engine for designing drugs.
preclinical results
Research results from before human testing.
What happened
Isomorphic Labs, an AI company that designs new medicines, announced a $5 billion Series C on November 17. The round was co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz, also called a16z, joined as a new investor. Alphabet and the company’s existing backers also invested.
The money will scale IsoDDE, Isomorphic Labs’ drug-design engine. It will also expand the company’s AI-designed medicine pipeline. Some money will build systems for translational and clinical development. TechCrunch reported that the company raised $2.1 billion in a Series B in May. The new round came only months later.
The background
Isomorphic Labs was spun out of Google DeepMind in 2021. Its work builds on AlphaFold, DeepMind’s AI system for predicting protein structures from genetic sequences. Isomorphic Labs combines that foundation with simulation models that explore chemistry. It uses those tools to design possible medicines.
The company said its program produced positive preclinical results in oncology and immunology. Preclinical work happens before human trials. The company also has partnerships with Eli Lilly, Novartis, and Johnson & Johnson.
Why the funding matters
The announcement points to a change in the company’s goal. It is moving beyond designing drug ideas. It wants to prepare those ideas for testing in people.
That requires more than a model that suggests molecules. Isomorphic Labs plans to build a complete path. That path includes drug design, candidate selection, translational research, and clinical development. Translational research connects a laboratory finding with a possible treatment.
The scale of the round also makes the next test clearer. Investors have put major capital behind the company’s approach. However, the $5 billion does not prove that any medicine works. It funds more design, experiments, and development work. The medical result still has to be demonstrated.
What is confirmed
The funding amount, lead investors, and planned uses come from the company’s announcement. TechCrunch provided additional context about the round. Isomorphic Labs says its program has produced positive preclinical results. That is not the same as positive results in human patients.
The company has not disclosed its new valuation. The announcement also does not say that a human trial has started. It says the money will help move candidates toward clinical trials.
What remains unknown
The company has not named the first candidate for human testing. It has not announced a first trial date or a specific disease for that trial. It has also not published enough detail here to judge the preclinical results.
We do not yet know whether its AI-designed candidates will show useful effects in people. We also do not know whether the new capital will produce a medicine that reaches approval.
What to watch next
The next milestones are concrete. Watch for a named candidate, a registered clinical trial, and a disclosed start date. Then watch the trial design, safety findings, and effectiveness data.
The important question is not only how much money Isomorphic Labs raised. It is whether the company can turn computer-designed ideas into reproducible results in people.
Sources: Isomorphic Labs’ official announcement, TechCrunch’s report.
Isomorphic Labs raises $5 billion for AI-designed medicine
📰 Full story: Isomorphic Labs raises $5 billion to move AI-designed drugs toward human trials
The company wants to move medicine ideas toward human trials. Its funding does not prove success.
Series C
A large investment round for a growing company.
pipeline
A group of medicine projects at different stages.
preclinical
Testing done before people use a medicine.
💡 The gist
- Isomorphic Labs raised $5 billion for AI-designed medicine.
- It wants to move medicine ideas toward human trials.
- The money does not prove any medicine works.
Isomorphic Labs is an AI company that designs medicines. It announced a $5 billion Series C funding round. A Series C is a large investment for a growing company. Greenoaks and Sequoia Capital led the round. Andreessen Horowitz joined. Alphabet and earlier investors also invested.
The company plans to use the money in several ways. It will grow IsoDDE. IsoDDE is its AI engine for designing drugs. It will expand its pipeline too. A pipeline is a group of medicine projects at different stages.
The company will also build systems for clinical development. Clinical development means preparing and testing medicines with people. This matters because drug design is only an early step. A computer can suggest a possible medicine. Researchers must study that suggestion. They must check how it behaves. They must also check safety before human testing.
Isomorphic Labs began as a Google DeepMind spinout in 2021. Its work builds on AlphaFold. AlphaFold predicts the shapes of proteins. The company combines that foundation with chemistry simulation models.
Isomorphic Labs said it saw positive preclinical results. Preclinical means testing before people use a medicine. The company mentioned cancer and immune-system programs. It also works with Eli Lilly, Novartis, and Johnson & Johnson.
TechCrunch reported that the company raised $2.1 billion in May. The new round followed only months later. That shows strong investor support. It does not show that trials will succeed.
The announcement does not say a human trial has started. It does not name the first drug candidate. It gives no trial date. The company has not disclosed its new valuation.
The next evidence will be concrete. Watch for a named candidate. Watch for a registered clinical trial. Then watch its safety and effectiveness results. A huge funding round shows belief from investors. It is not the same as a successful medicine.
Sources: Isomorphic Labs announcement, TechCrunch report.
A medicine company gets a very big pile of money
📰 Full story: Isomorphic Labs raises $5 billion to move AI-designed drugs toward human trials
Isomorphic Labs uses AI to help plan medicines. It announced $5 billion.
clinical trials
Tests that give a medicine to people.
preclinical work
Early medicine checks before people try it.
Isomorphic Labs
A company using AI to plan medicines.
Isomorphic Labs is a company that uses AI for medicine. It announced $5 billion in new money. It will use the money to plan medicines. It will get some medicine ideas ready for people tests. People tests are called clinical trials. First, computers study medicine ideas. Then, researchers check those ideas before people try them. That early checking is called preclinical work. The company says some tests looked positive. It mentioned cancer and the immune system. This does not mean a medicine is ready. No human trial has been announced yet. No first medicine has been named. We do not know when testing will begin. More money can help the work continue. But money cannot promise a cure. Next, people will watch for a named medicine. They will watch for human test results. Read the company announcement for details.